- Home
- ALGS vs SCLX Comparison
ALGS vs SCLX Comparison
Compare ALGS & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- SCLX
- Stock Information
- Founded
- ALGS 2018
- SCLX 2011
- Country
- ALGS United States
- SCLX United States
- Employees
- ALGS N/A
- SCLX N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- SCLX Health Care
- Exchange
- ALGS Nasdaq
- SCLX Nasdaq
- Market Cap
- ALGS 36.0M
- SCLX 28.4M
- IPO Year
- ALGS 2020
- SCLX N/A
- Fundamental
- Price
- ALGS $5.29
- SCLX $5.12
- Analyst Decision
- ALGS Strong Buy
- SCLX Strong Buy
- Analyst Count
- ALGS 1
- SCLX 4
- Target Price
- ALGS $70.00
- SCLX $396.67
- AVG Volume (30 Days)
- ALGS 163.7K
- SCLX 146.9K
- Earning Date
- ALGS 05-06-2025
- SCLX 05-14-2025
- Dividend Yield
- ALGS N/A
- SCLX N/A
- EPS Growth
- ALGS N/A
- SCLX N/A
- EPS
- ALGS N/A
- SCLX N/A
- Revenue
- ALGS $3,270,000.00
- SCLX $50,710,000.00
- Revenue This Year
- ALGS N/A
- SCLX $115.30
- Revenue Next Year
- ALGS N/A
- SCLX $73.33
- P/E Ratio
- ALGS N/A
- SCLX N/A
- Revenue Growth
- ALGS N/A
- SCLX 7.79
- 52 Week Low
- ALGS $3.76
- SCLX $3.60
- 52 Week High
- ALGS $46.80
- SCLX $80.50
- Technical
- Relative Strength Index (RSI)
- ALGS 43.20
- SCLX 48.72
- Support Level
- ALGS $5.47
- SCLX $4.43
- Resistance Level
- ALGS $6.12
- SCLX $5.94
- Average True Range (ATR)
- ALGS 0.60
- SCLX 0.54
- MACD
- ALGS 0.12
- SCLX 0.25
- Stochastic Oscillator
- ALGS 37.30
- SCLX 59.41
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.